Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
grade A 13.94 -0.89% -0.13
CYTK closed down 0.89 percent on Thursday, February 27, 2020, on 1.15 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical CYTK trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Fell Below 20 DMA Bearish -0.89%
1,2,3 Pullback Bullish Bullish Swing Setup -0.89%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.89%
1,2,3 Pullback Bullish Bullish Swing Setup -5.30%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.30%
Pocket Pivot Bullish Swing Setup -5.30%
Outside Day Range Expansion -5.30%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Biopharmaceutical Diseases Disease Neuroscience Serious Diseases Anatomy Heart Failure Amyotrophic Lateral Sclerosis Nervous System Treatment Of Heart Failure Astellas Pharma Treatment Of Serious Diseases

Is CYTK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 16.96
52 Week Low 5.75
Average Volume 832,996
200-Day Moving Average 11.61
50-Day Moving Average 12.61
20-Day Moving Average 14.50
10-Day Moving Average 15.05
Average True Range 0.84
ADX 39.95
+DI 20.46
-DI 21.36
Chandelier Exit (Long, 3 ATRs ) 14.45
Chandelier Exit (Short, 3 ATRs ) 14.58
Upper Bollinger Band 16.52
Lower Bollinger Band 12.48
Percent B (%b) 0.36
BandWidth 27.90
MACD Line 0.59
MACD Signal Line 0.83
MACD Histogram -0.2386
Fundamentals Value
Market Cap 748.1 Million
Num Shares 53.7 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -41.00
Price-to-Sales 6.91
Price-to-Book 3.91
PEG Ratio -0.34
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.12
Resistance 3 (R3) 16.14 15.45 15.75
Resistance 2 (R2) 15.45 14.89 15.43 15.63
Resistance 1 (R1) 14.69 14.55 15.07 14.67 15.51
Pivot Point 14.00 14.00 14.19 13.98 14.00
Support 1 (S1) 13.24 13.44 13.62 13.22 12.37
Support 2 (S2) 12.55 13.10 12.53 12.25
Support 3 (S3) 11.79 12.55 12.13
Support 4 (S4) 11.77